The phosphatidyl inositol 3-kinase (PI3K)/Akt pathway is activated downstream of a variety of extracellular signals and activation of this signaling pathway impacts a number of cellular processes including cell growth, proliferation and survival. The alteration of components of this pathway, through either activation of oncogenes or inactivation of tumor suppressors, disrupts a signaling equilibrium and can thus lead to cellular transformation. The frequent dysregulation of the PI3K/Akt pathway in human cancer has made components of this pathway attractive for therapeutic targeting; however, a more comprehensive understanding of the signaling intricacies is necessary to develop pharmacological agents to target not only specific molecules, but also specific functions. Here, we review a series of experiments examining the contribution of molecules of this signaling network including PI3K, phosphatase and tensin homolog deleted on chromosome 10, integrin-linked kinase and Akt and address the significance to human breast cancer.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Molecular Cancer Open Access 18 August 2023
Cancer Cell International Open Access 05 March 2022
Nalbuphine suppresses breast cancer stem-like properties and epithelial-mesenchymal transition via the AKT-NFκB signaling pathway
Journal of Experimental & Clinical Cancer Research Open Access 15 May 2019
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Ackler S, Ahmad S, Tobias C, Johnson MD, Glazer RI . (2002). Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene 21: 198–206.
Ahmed N, Riley C, Oliva K, Stutt E, Rice GE, Quinn MA . (2003). Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J Pathol 201: 229–237.
Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R et al. (2003). Overexpression of Akt2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63: 196–206.
Attwell S, Roskelley C, Dedhar S . (2000). The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 19: 3811–3815.
Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772–775.
Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA et al. (1995). Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280–285.
Brakebusch C, Fassler R . (2003). The integrin-actin connection, an eternal love affair. EMBO J 22: 2324–2333.
Bravou V, Klironomos G, Papadaki E, Taraviras S, Varakis V . (2006). ILK over-expression in human colon cancer progression correlates with activation of β-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. J Pathol 208: 91–99.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96: 857–868.
Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T et al. (2001). Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. Genes Dev 15: 2203–2208.
Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw III EB et al. (2001a). Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292: 1728–1731.
Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ . (2001b). Akt1/PKBα is required for normal growth but dispensible for maintenance of glucose homeostasis in mice. J Biol Chem 276: 38349–38352.
Chung DH, Lee JI, Kook MC, Kim JR, Kim SH, Choi EY et al. (1998). ILK (beta1-integrin-linked protein kinase): a novel immunohistochemical marker for Ewing's sarcoma and primitive neuroectodermal tumour. Virchows Arch 433: 113–117.
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA . (1995). Inhibition of glycogen cynthase kinase-3 by insulin mediated protein kinase B. Nature 378: 785–789.
Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T et al. (1997). Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57: 4710–4713.
Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D et al. (2003). Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 9: 4409–4414.
D'Amico M, Hulit J, Amanatullah DF, Zafonte BT, Albanese C, Bouzahzah B et al. (2000). The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 275: 32649–32657.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231–241.
del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G . (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687–689.
Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S . (1998). Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 95: 11211–11216.
Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH . (1997). Phosphorylation and activation of heart glucose 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascade. J Biol Chem 272: 17269–17275.
Diehl JA, Cheng M, Roussel MF, Sherr CJ . (1998). Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499–3511.
Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS et al. (2005). Role for Akt3/protein kinase Bγ in attainment of normal brain size. Mol Cell Biol 25: 1869–1878.
Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S . (2005). Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 24: 3596–3605.
Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L et al. (1999). Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57: 237–243.
Graff JR, Deddens JA, Konicek BW, Colligan BM, Hurst BM, Carter HW et al. (2001). Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res 7: 1987–1991.
Hanahan D, Weinberg RA . (2000). The hallmarks of cancer. Cell 100: 57–70.
Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J et al. (1996). Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379: 91–96.
Hennessy BT, Smith DL, Ram PT, Lu T, Mills GB . (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Disc 4: 988–1004.
Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ . (2001). Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21: 2203–2212.
Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ . (2004). Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res 64: 3171–3178.
Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N et al. (2005). Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 171: 1023–1034.
Kane LP, Shapiro VS, Stokoe D, Weiss A . (1999). Induction of NF-κB by the Akt/PKB kinase. Curr Biol 9: 601–604.
Kang S, Bader AG, Vogt PK . (2005). Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102: 802–807.
Kawakami Y, Nishimoto H, Kitaura J, Maeda-Yamamoto M, Kato RM, Littman DR et al. (2004). Protein kinase C βII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem 279: 47720–47725.
Kohn AD, Summers SA, Birnbaum MJ, Roth RA . (1996). Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271: 31372–31378.
Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ et al. (2005). Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4: 1681–1688.
Larue L, Bellacosa A . (2005). Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene Rev 24: 7443–7454.
Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N et al. (2002). Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129: 4159–4170.
Li Y, Corradetti MN, Inoki K, Guan KL . (2004). TSC2: Filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 29: 32–38.
Li Y, Podsypanina K, Liu X, Crane A, Tan LK, Parsons R et al. (2001). Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2: 2–10.
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z et al. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64–67.
Lynch DK, Ellis CA, Edwards PA, Hiles ID . (1999). Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene 18: 8024–8032.
Mackinnon AC, Qadota H, Norman KR, Moerman DG, Williams BD . (2002). C. elegans PAT-4/ILK functions as an adaptor protein within integrin adhesion complexes. Curr Biol 12: 787–797.
Marotta A, Tan C, Gray V, Malik S, Gallinger S, Sanghera J et al. (2001). Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene 20: 6250–6257.
Minobe K, Bando K, Fukino K, Soma S, Kasumi F, Sakamoto G et al. (1999). Somatic mutation of the PTEN/MMAC1 gene in breast cancers with microsatellite instability. Cancer Lett 144: 9–16.
Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ et al. (1999). Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274: 21528–21532.
Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H et al. (1997). Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6: 1383–1387.
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Donner DB . (1999). NF-κB activation by tumor necrosis factor required the Akt serine-threonine kinase. Nature 401: 82–85.
Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J et al. (2000). Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97: 3207–3212.
Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D et al. (2001). Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase. Critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 276: 27462–27469.
Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J . (1997). Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57: 3657–3659.
Romashkova JA, Makarov SS . (1999). NF-κB is a target of AKT in anti-apoptotic PDGF signaling. Nature 401: 86–90.
Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ErbB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554–2559.
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
Sarbassov DD, Guertin DA, Ali AM, Sabatini DM . (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101.
Schwertfeger KL, McManaman JL, Palmer CA, Neville MC, Anderson SM . (2003). Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactation. J Lipid Res 44: 1100–1112.
Schwertfeger KL, Richert MM, Anderson SM . (2001). Mammary gland involution is delayed by activated akt in transgenic mice. Mol Endocrinol 15: 867–881.
Sizemore N, Leung S, Stark GR . (1999). Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subunit. Mol Cell Biol 19: 4798–4805.
Stal O, Perez-Tenotio G, Akerberg L, Olsson B, Nordenskjold B, Skoog L et al. (2003). Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5: R37–R44.
Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW . (2000). High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/− mice. Cancer Res 60: 3605–3611.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356–362.
Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma X et al. (2001). AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159: 431–437.
Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K et al. (2004). Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5: 79–90.
Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C et al. (1997). MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57: 5221–5225.
Thant AA, Nawa A, Kikkawa F, Ichigotani Y, Zhang Y, Sein TT et al. (2000). Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis 18: 423–428.
Toker A, Newton AC . (2000). Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 275: 8271–8274.
Tschopp O, Yang Z-Z, Brodbeck D, Duemmler B, Hemmings-Mieszczak M, Watanabe T et al. (2005). Essential role of protein kinase Bγ (PKBγ/Akt3) in postnatal brain development, but not for glucose homeostasis. Development 132: 2943–2954.
Tu Y, Huang Y, Zhang Y, Hua Y, Wu C . (2001). A new focal adhesion protein that interacts with integrin-linked kinase and regulates cell adhesion and spreading. J Cell Biol 153: 585–598.
Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D et al. (2002). Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8: 1136–1144.
Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H . (2006). Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 103: 1480–1485.
West KA, Castillo SS, Dennis PA . (2002). Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Update 5: 234–248.
White DE, Cardiff RD, Dedhar S, Muller WJ . (2001). Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 20: 7064–7072.
Wu C . (2001). ILK interactions. J Cell Sci 114: 2549–2550.
Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino M, Goicoechea S et al. (1998). Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem 273: 528–536.
Yamaji S, Suzuki A, Sugiyama Y, Koide Y, Yoshida MKH, Mohri H et al. (2001). A novel integrin-linked kinase-binding protein, affixin, is involved in the early stage of cell-substrate interaction. J Cell Biol 153: 1251–1264.
Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A . (2005). Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 20: 539–550.
Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y et al. (2005). Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 4: 1146–1156.
Zervas CG, Brown NH . (2002). Integrin adhesion: when is a kinase a kinase? Curr Biol 152: R350–R351.
Zervas CG, Gregory SL, Brown NH . (2001). Drosophila integrin-linked kinase is required at sites of integrin adhesion to link the cytoskeleton to the plasma membrane. J Cell Biol 12: 1007–1018.
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC . (2001). Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3: E71–E73.
WJM is supported by CRC Chair in Molecular Oncology. RLD is supported by a pre-doctoral award from the DOD. This work was supported by grants from NCI PPG #102036 and CBCRA awarded to WJM.
About this article
Cite this article
Dillon, R., White, D. & Muller, W. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26, 1338–1345 (2007). https://doi.org/10.1038/sj.onc.1210202
- breast cancer
This article is cited by
Molecular Cancer (2023)
Cancer Cell International (2022)
Attenuation of ROS-mediated myocardial ischemia–reperfusion injury by morin via regulation of RISK/SAPK pathways
Pharmacological Reports (2020)
Nalbuphine suppresses breast cancer stem-like properties and epithelial-mesenchymal transition via the AKT-NFκB signaling pathway
Journal of Experimental & Clinical Cancer Research (2019)
Molecular Cancer (2019)